S-1/A: Lucy Scientific Discovery Inc. Files Amendment No. 2 to Form S-1 Registration Statement for Share Resale and Potential Warrant Proceeds

Lucy Scientific Discovery Inc. has filed an amendment to its registration statement for the offer and resale of up to 7,361,688 common shares by selling stockholders, with potential proceeds from warrant exercises to be used for working capital.

Summary

• Lucy Scientific Discovery Inc. has filed Amendment No. 2 to its Form S-1 registration statement with the SEC.
• The filing pertains to the offer and resale of up to 7,361,688 common shares by selling stockholders.
• These shares include those issuable upon conversion of senior secured convertible promissory notes, exercise of warrants, and a minimum equity interest payment.
• The company will not receive proceeds from the sale of shares by the selling stockholders, but may receive approximately $375,000 if all warrants are exercised for cash.
• These proceeds would be used for working capital and general corporate purposes.
• The selling stockholders will bear their selling expenses, while the company will cover registration costs.
• The company's common shares are listed on The Nasdaq Capital Market under the symbol LSDI.
• The last reported sale price for the company's common shares on Nasdaq was $0.2356 per share on February 21, 2024.
• The document highlights recent developments including agreements with Hightimes, Wesana Health, and Bluesky Biologicals, as well as changes in management.
• The company is an emerging growth company and a smaller reporting company, which allows for reduced reporting requirements.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are potential positives such as the warrant proceeds and agreements with other companies, the concerns about the company's ability to continue as a going concern and the need to regain Nasdaq compliance weigh heavily on the overall outlook.

Positives

• Potential influx of $375,000 in gross proceeds if all warrants are exercised, which would be used for working capital.
• The company has agreements with Hightimes, Wesana Health, and Bluesky Biologicals.
• The company is an emerging growth company and a smaller reporting company, which allows for reduced reporting requirements.

Negatives

• The company will not receive any proceeds from the sale of common shares by the selling stockholders.
• The company's independent auditors have raised concerns about the company's ability to continue as a going concern.
• The company has incurred significant operating losses since inception.
• The company needs to regain compliance with the Nasdaq minimum bid price requirement by March 19, 2024, subject to possible extensions.
• The company's growth depends on completing acquisitions of Bluesky and Hightimes intellectual property, which are subject to Nasdaq approval.

Risks

• The company's independent auditors have raised concerns about the company's ability to continue as a going concern.
• Failure to maintain compliance with Nasdaq listing requirements could result in delisting.
• The growth of the business depends on completing the acquisitions of Bluesky and the intellectual property of Hightimes, which are subject to Nasdaq approval.
• Future capital raises may dilute existing stockholders' ownership.
• The company may experience extreme stock price volatility unrelated to its actual or expected operating performance, financial condition or prospects.

Future Outlook

The company intends to monitor the psychedelic marketplace and revisit the Dealer License when the regulatory landscape provides for a clearer path to meaningful revenues. The company expects to continue to rely on reduced reporting requirements as an emerging growth company and smaller reporting company.

Industry Context

The document references the growing market for psychoactive alternatives, citing a Forbes prediction that it will double to over $5 billion in gross sales by 2025, suggesting the company is positioning itself to capitalize on this trend.

Management Changes

Related Party Transactions

• Paul Abramowitz, one of the company's directors, is a shareholder of Hightimes and is the stepfather of the person who was Executive Chairman of Hightimes through September 2023.
• Mr. Abramowitz's biological son is a beneficial owner of Whistling Pines LLC, one of the Selling Stockholders.

Stakeholder Impact

• Existing shareholders may experience dilution from future capital raises and the issuance of shares for acquisitions.
• The company's ability to continue as a going concern impacts all stakeholders, including employees, suppliers, and creditors.
• The potential delisting from Nasdaq could negatively impact shareholder value and liquidity.

Next Steps

• The company needs to regain compliance with the Nasdaq minimum bid price requirement by March 19, 2024.
• The company will continue to monitor the closing bid price of its Common Shares and seek to regain compliance with all applicable Nasdaq requirements within the allotted compliance period.
• The company intends to monitor the psychedelic marketplace and revisit the Dealer License when the regulatory landscape provides for a clearer path to meaningful revenues.

Key Dates

Keywords

common shares, selling stockholders, registration statement, warrants, Lucy Scientific Discovery, Nasdaq, convertible notes, offering, Bluesky, Hightimes